Woodbury, Michel Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2009
NCT01875822
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Michel Woodbury, M.D. | Woodbury, Michel, M.D.

Active Ingredients

Drugs in Phase 2 Trials (1)

curcumin (1 trial)

Drugs in Phase 1 Trials (1)

scelectium tortuosum (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2